MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Total Debt
Short-term and long-term borrowings combined.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Total Debt · Q3 FY2026 · quarter ended Sep 2026
Total debt rises 428.3% from a year ago
Total debt stood at $3.29M at the end of Q3 FY2026, up 428.3% from a year earlier and down 1.5% from the prior quarter. Over 3 fiscal years it compounded at +8.9% a year.
Context
- Total debt amounted to 0.7% of total assets at the end of Q3 FY2026, up 0.5 pp from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +428.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 596K USD
- Year-over-year change
- +248.5%
- 3-year CAGR
- +8.9%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 596K | +248.5% |
| FY2024 | 2024-12-31 | 171K | -47.2% |
| FY2023 | 2023-12-31 | 324K | -29.7% |
| FY2022 | 2022-12-31 | 461K | — |
Total Debt vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +428.3% is the 2nd highest of 8, against a peer median of -15.1%.
- Total debt amounts to 0.7% of total assets for MBX, versus a peer median of 1.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €447.81M EUR | -45.0% | +12.2% | 18.4% | |
| Mar 2026 | $37.33M USD | -86.1% | -42.4% | 9.5% | |
| Mar 2026 | $35.85M USD | +2158.8% | +216.7% | 10.7% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $10.22M USD | — | — | 0.8% |
| Jun 2026 | $4.09M USD | +365.4% | -55.6% | 0.8% | |
| Sep 2026 | $3.52M USD | -15.1% | +27.1% | 0.8% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $3.29M USD | +428.3% | +8.9% | 0.7% |
| Mar 2026 | $1.24M USD | -84.4% | -11.4% | 2.7% | |
| Mar 2026 | $761K USD | +152.8% | -2.6% | 0.3% | |
| Peer median (excluding MBX) | — | -15.1% | -2.6% | 1.8% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.